SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a highly volatile spotlight following a public endorsement from President Trump, which has ignited intense debate between bulls citing the company's critical role in national security and bears echoing Michael Burry's skepticism regarding its valuation and competitive threats. The community remains sharply divided, with active discussion focused on whether the stock is primed for a major short squeeze driven by institutional accumulation or if it faces further downside as it navigates a challenging sector-wide software sell-off.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending as investors weigh conflicting indicators of institutional accumulation and ETF inflows against persistent geopolitical volatility and broader market uncertainty. Community sentiment remains deeply polarized, with active debates centered on whether current price levels represent a bottom-tier accumulation zone or a precursor to further macroeconomic instability.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is surging amid high-volume trading and speculative buzz surrounding its role as a decentralized entertainment protocol, with community members debating whether the rapid valuation jump is a sustainable momentum play or an overextended market trend. Discussion is heavily focused on the project's roadmap of global music events and perceived potential for future institutional partnerships, even as vocal skeptics warn of volatility risks and potential price manipulation.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors rally behind a new multi-billion dollar strategic partnership with Nvidia that integrates their respective AI infrastructure and custom chip ecosystems. The community is actively discussing the stock's breakout potential as it reclaims key resistance levels, with many traders focusing on the company's surging optics business and long-term positioning within the AI supply chain.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors react to a combination of strong institutional volume, potential gamma squeeze setups on heavy call option activity, and renewed confidence in its role within the AI optical infrastructure supply chain. The community is actively debating the company's long-term commercial execution and strategic partnerships, with bullish sentiment focusing on the scaling of their Optical Interposer platform despite ongoing volatility and high-risk positioning.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging as investors closely monitor topline results from its Phase 2/3 OptimUM-02 trial evaluating darovasertib in metastatic uveal melanoma. The community is actively debating the potential for an accelerated approval filing and questioning the significance of the partnership with Servier ahead of this high-stakes data release.

Maulcoin

Maulcoin is trending as a community-driven "culture coin" that has gained significant traction on social sentiment platforms despite lacking a formal price chart. Holders are actively discussing their long-term conviction, referring to themselves as "Maulers" while organizing to build support, manage liquidity, and execute coordinated buying efforts in pursuit of a zero-erasing movement.

WorldFinancial

WorldFinancial (WLFI) is currently polarizing the market, with bulls pointing to upcoming catalysts like the Mar-a-Lago crypto forum and potential institutional adoption, while skeptics view the token as a manipulated pump-and-dump scheme. The community is deeply divided between those betting on long-term utility and political alignment versus traders warning of significant dilution risks and historical volatility associated with the project.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as the community anticipates major near-term catalysts, including upcoming Phase 3 trial completions and pancreatic cancer data presentations at the Digestive Disease Week conference. Investor sentiment remains heavily bullish, driven by the companys strong cash position, recent analyst price target upgrades, and the high-conviction belief that its proprietary alpha-radiation technology is significantly undervalued.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the company's electro-optic polymer technology as a scalable solution for AI data centers. The community is actively debating the transition from R&D to foundry-integrated manufacturing, with recent partnerships and expectations of upcoming tape-out results driving volatility and speculation about potential industry adoption.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena Announces Leadership Team Updates

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...

AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa

AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.

Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease

SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.

JPMorgan Chase & Co. Buys 608,814 Shares of Prothena Corporation plc $PRTA

JPMorgan Chase & Co. lifted its stake in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) by 479.6% during the third quarter, according to the company in its most recent Form 13F filing...

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts

Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) has been assigned a consensus rating of "Hold" from the eleven ratings firms that are currently covering the firm, MarketBeat.com reports. Two...

Why Is Jazz (JAZZ) Down 3.9% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet

The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Prothena (NASDAQ:PRTA) Shares Cross Below Two Hundred Day Moving Average   - Here's What Happened

Prothena (NASDAQ:PRTA) Share Price Crosses Below 200-Day Moving Average - Time to Sell...

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

PRTA
Prothena Corporation plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PRTA News

PRTAProthena Corporation plc